Shihori Tanabe
Shihori Tanabe, a holder of PhD degree, is a senior researcher at Division of Risk Assessment, Center for Biological Safety and Research in National Institute of Health Sciences (NIHS). She completed her doctorate in pharmaceutical science with the field in molecular biology and pharmacology at the University of Tokyo. She also performed the research mainly focused on biochemistry and cellular biology in College of Medicine, University of Illinois at Chicago. A part of her research is focused on gene expression profiling and finding important factors of various cells including cancer cells and stem cells using bioinformatics approach including microarray and real-time RT-PCR techniques. She has also conducted research such as cellular signaling, cardiac cell research and protein regulation mechanism, and made contribution in the field of molecular biology, pharmacology and biochemistry. Her present research interest is in analyzing molecular networks and profiling cancer cells and stem cells in terms of cellular phenotype and cellular signaling. She is also interested in finding essential factors to distinguish cancer cell types for revealing mechanism of cancer development and safe application of the cells as cellular therapeutics in regenerative medicine, as well as in assessing the long-term influences of the alteration in gene expression and cellular phenotype from the point of view of regulatory science. She has been a delegate for the Japanese Society for Regenerative Medicine, a councilor for Society for Regulatory Science of Medical Products, a delegate for the Pharmaceutical Society of Japan, an international associate for the Japanese Pharmacological Society, an editorial board member for several journals including Journal of Toxicological Sciences, Fundamental Toxicological Sciences, World Journal of Stem Cells, Journal of Medical Genomics and Biomarkers, and Artificial Intelligence in Cancer, an Editor-in-Chief for Journal of Clinical and Medical Research, Advances in Clinical and Medical Research, and Journal of Clinical Epigenetics, a Book Editor for "Cancer Stem Cell Markers and Related Network Pathways" in Springer Nature, an Executive Editor for Research Journal of Oncology, an Editor for Topical Collection of Cancers, a Topic Editor for Frontiers in Oncology, and a Guest Associate Editor for Frontiers in Cell and Developmental Biology. She leads Adverse Outcome Pathway (AOP) Coach Team and is a co-lead of External Review subgroup in OECD Extended Advisory Group on Molecular Screening and Toxicogenomics (EAGMST).
Abstracts this author is presenting: